AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00512759
Drug: Goal-directed preload and afterload decrement
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early goal-directed preload and afterload decrement with a target systolic blood pressure (RR) of 90-110 mmHg for the entire hospitalization using sublingual nitrates (Nitroglycerin Streuli®) or nitrospray (Corangin Nitrospray®) transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).
Trial: NCT01343719
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for administration
Trial: NCT00270491
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01097135
Drug: Duraprep Surgical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005854
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005854
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00447213
Drug: Human Insulin Inhalation Powder
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient specific dose, inhaled, before meals,12 weeks
Trial: NCT02016924
Drug: DRV
RxNorm normalized name: Urinal Male Drv RTLPC23201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered once daily according to dosing recommendations per product monograph
Trial: NCT02016924
Drug: LPV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution administered orally
Trial: NCT02016924
Drug: Third Unboosted Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATV (administered orally), DRV (administered orally), and LPV/r (administered orally) would be general list but unspecified for sites.
Trial: NCT02016924
Drug: F/TAF TOS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral suspension
Trial: NCT04339777
Drug: Cyclophosphamide (Cytoxan)
RxNorm normalized name: cyclophosphamide Oral Tablet [Cytoxan]
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide: 50 mg/kg IV once daily over 2 hours on days +3 and +4, dosed according to ideal body weight
Trial: NCT03888144
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg of ketorolac taken by mouth every 6 hours for 5 days
Trial: NCT00967850
Drug: Intravitreal Injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of 1,25 mg in 0,05 ml
Trial: NCT00967850
Drug: Photodynamic Therapy (Visudyne)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy on day 1 as described in standard clinical guidelines.
Trial: NCT01863680
Drug: Gonadotropin-releasing hormone (GnRH) analogue
RxNorm normalized name: Gonadotropin releasing hormone analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will undergo conventional controlled ovarian stimulation (COS) therapy for in-vitro Fertilization and Embryo Transfer (IVF/ET) according to the Investigator's discretion using GnRH analogue (agonist or antagonist) preparation.
Trial: NCT04489446
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients allocated to this arm will receive a matching placebo similar to Sildenafil pills used in the intervention arm. Placebos will be delivered orally every 8 hours for up to seven consecutive days.
Trial: NCT01448746
Drug: low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg 12 hours before surgery and 12 hours later surgery
Trial: NCT02244944
Drug: EZ-Urso combination therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day
Trial: NCT04830449
Drug: HCP1904-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once daily for 8 weeks orally.
Trial: NCT04830449
Drug: RLD2001-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once daily for 8 weeks orally.
Trial: NCT03821376
Drug: Contrast enhanced ultrasound with Lumason
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following consent, they will undergo contrast enhanced ultrasound of their known renal mass(es). This will be performed at University hospital following intravenous administration of Lumason (2.5 mL per injection, maximum of 2 injections per mass).
Trial: NCT03581071
Drug: TS-143
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00519480
Drug: GSK189075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK189075 will be available as an oral tablet with dosing strengths of 500 milligrams and 250 milligrams.
Trial: NCT00519480
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be available as an oral tablets.
Trial: NCT00137332
Drug: GAP-486 (ZP-123)
RxNorm normalized name: GAP JUNCTION ALPHA-3 PROTEIN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01144312
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: an initial intravenous bolus of fentanyl 100 μg and infusion of fentanyl at variable rates ranging from 250 to 400 μg/hr
Trial: NCT03689010
Drug: Finacea® (Azelaic acid Foam) 15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelaic acid foam 15%
Trial: NCT03689010
Drug: Vehicle of the test product
RxNorm normalized name: The Magic Bullet Rectal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle of the test product
Trial: NCT02621606
Drug: [11C]MK-6884
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV bolus dose of \~370 MBq \[11C\]MK-6884
Trial: NCT02044510
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo capsules to the intervention arm
Trial: NCT01813799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
Trial: NCT00875394
Drug: Comparator: Antidiabetic Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient can take any oral antidiabetic drug (other than metformin)
Trial: NCT03455075
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules that look like DMAU and LNG capsules but with no active ingredients.
Trial: NCT00290940
Drug: CS-917
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01229345
Drug: Breakfast & exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1859 kJ breakfast vs fast, exercise at 60% maximum aerobic capacity to expend 1859 kJ.
Trial: NCT04409964
Drug: Remifentanil Hydrochloride
RxNorm normalized name: Remifentanil Hydrochloride
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
Trial: NCT01259713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match liposomal amphotericin B administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
Trial: NCT01732393
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004010
Drug: ABVD regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004010
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004010
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003457
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adults with a persistent or recurrent brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
Trial: NCT02199847
Drug: Pharmaton® Caplets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02199847
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01492881
Drug: pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous, 30mg/m2, Day 4
Trial: NCT02566395
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 60 mg/kg IV daily x 2 consecutive days
Trial: NCT02246998
Drug: RTV
RxNorm normalized name: Accu-Chek SmartView Test Strips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tablet administered orally once daily with food
Trial: NCT02246998
Drug: ABC/3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600/300 mg FDC tablet administered orally once daily with food
Trial: NCT01601808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally once a day, continuously throughout the study
Trial: NCT03030066
Drug: DS-1001b
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic not assigned
Trial: NCT03070730
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: t.i.d
Trial: NCT02052349
Drug: ABT-333
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of ABT-333
Trial: NCT00004179
Drug: CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004179
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004179
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01982916
Drug: AGR tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01982916
Drug: Placebo (for AGR tablet and/or Active Comparator)
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00044044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo to Lurasdione and Haloperidol
Trial: NCT02257697
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02943135
Drug: placebo in-situ gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo in-situ gel
Trial: NCT01152619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous repeated dose
Trial: NCT03871387
Drug: Deep Group
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~* Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 0 \& PTC= 1\~2 (TOF = train-of-four. PTC = post-tetanic count)~* TOF and PTC are assessed by acceleromyography (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~* At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme \[MSD\], Oss, the Netherlands) injection to reverse muscle relaxation.~* Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2
Trial: NCT03871387
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~* Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 1\~2~* TOF and PTC are assessed by acceleromyograph (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~* At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme \[MSD\], Oss, the Netherlands) injection to reverse muscle relaxation.~* Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2
Trial: NCT02417246
Drug: Generic A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This medication will be taken for 7 days
Trial: NCT02417246
Drug: Generic B
RxNorm normalized name: Generic B-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This medication will be taken for 7 days
Trial: NCT04603989
Drug: HNC042 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, doses: 300mg to 1200mg
Trial: NCT04603989
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo , Intravenous route , multiple ascending doses
Trial: NCT01001494
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice-daily by inhalation for 24 weeks
Trial: NCT00406029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID capsules
Trial: NCT00406029
Drug: Other Parkinson's Disease treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.
Trial: NCT01152619
Drug: RO4989991
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous repeated dose
Trial: NCT03283137
Drug: TGR-1202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGR-1202 will be given at a dose of 600mg (dose level 1) or 800mg (dose level 2). If the dose of 600mg is tolerated in the first cohort, then the dose will be increased to 800mg which is the only and final dose escalation. If the dose of 600mg is not tolerated, then the dose will be decreased to 400mg daily.
Trial: NCT03078101
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally once daily
Trial: NCT00351884
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03761264
Drug: Odontopaste®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teeth with abscess will be opened from the crown to allow cleaning of the canals following which the Odontopaste® will be placed in the canals and the pulp chamber. Cavity will be sealed with capsulated Glass ionomer cement.
Trial: NCT05574543
Drug: AGA111
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
Trial: NCT05574543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
Trial: NCT00703807
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level -1, 5 mg qod Dose level 1, 5 mg qod Dose level 2, 5 mg qd Dose level 3, 5 mg qd DOse level 4, 10 mg qd
Trial: NCT00782080
Drug: Sedariston
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. John´s Wort (100 mg) Valerian Extract (50 mg)
Trial: NCT00782080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03336840
Drug: ProMetS probiotics powder
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4g (2 strips) of ProMetS probiotics powder administered orally every night
Trial: NCT02182037
Drug: BIBT 1011 BS placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01955460
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04106830
Drug: Intravenous steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study does not limit treatment methods.patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. The HD-S treatment course referred to intravenous administration of 1 g of glucocorticoid daily for 3 consecutive days and continuous dose 240 mg reduction for 60mg oral administration. Immunomodulatory therapies are necessary for the remission stage. The treatment methods include: Azathioprine (start at 50 mg per day, add 50 mg per week to 2 mg/kg.d); Mycophenolate Mofetil (The initial dose was 0.25g bid, add 0.5g per week to 0.75g bid); and Rituximab (500 mg on the 1st day, the 15th day, then 500mg per half year).
Trial: NCT02955186
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once per day for 8 days
Trial: NCT01746602
Drug: Timoptic® 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timoptic® 0.5% Eye Drops, Merck, single instillation
Trial: NCT01746602
Drug: Timophtal sine® 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timophtal sine® 0.5%, Agepha, Eye Drops, single instillation
Trial: NCT02658162
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
Trial: NCT01899144
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.
Trial: NCT02213757
Drug: Premarin vaginal estrogen cream
RxNorm normalized name: estrogens, conjugated (USP) Vaginal Cream [Premarin]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02213757
Drug: Placebo vaginal cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive vaginal cream manufactured to mimic Premarin vaginal cream
Trial: NCT00803244
Drug: 300 IR
RxNorm normalized name: ORALAIR 300 IR TAB,SL PKT 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 IR grass pollen allergen extract tablet starting 2 months before the grass pollen season and during the grass pollen season
Trial: NCT00803244
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sublingual tablet starting 2 months before the grass pollen season and during the grass pollen season
Trial: NCT00751881
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet~Oral administration
Trial: NCT00745264
Drug: Diractin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ketoprofen to 4 joints
Trial: NCT00745264
Drug: Diractin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 and 400 mg Ketoprofen used concomittant with heat
Trial: NCT00745264
Drug: Diractin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 and 400 mg Ketoprofen concomittant with moderate exercise
Trial: NCT03049540
Drug: Placebo 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
Trial: NCT01347684
Drug: Standard care using current drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Drug therapy
Trial: NCT04495712
Drug: spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aldosterone blocker
Trial: NCT04495712
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical in appearance to spironolactone study drug
Trial: NCT01129310
Drug: Irinotecan-Capecitabine-Oxaliplatin
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan-160mg/m2 IV infusion over 60-90 min on Day 1 Capecitabine-1900mg/m2 daily PO in divided doses (=950mg/m2 BID) on days 2-15 Oxaliplatin- 100mg/m2 IV infusion over 2 hours Day 1
Trial: NCT04044547
Drug: Placebo, extended-release microspheres
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four stable dose levels of placebo at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~* Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~* Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~* Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~* Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks.
Trial: NCT01190657
Drug: Selbex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg/day, 3 times/day, for 14 days
Trial: NCT01190657
Drug: Selbex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg/day, 3 times/day, for 56 days
Trial: NCT02985216
Drug: YHD1119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YHD1119 150mg, PO YHD1119 300mg, PO~YHD1119 600mg, PO
Trial: NCT02029157
Drug: ARQ197
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02029157
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00398528
Drug: IFN-β-1a, (Avonex®)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01123304
Drug: MORAb028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg MORAb-028 will be injected at either 1 mg/cm3 per day over 5 days for a total dose of 5 mg for the first cohort and 2 mg/cm3 for the second cohort. Subjects will receive MORAb-028 injections on Days: 1-5, 8-12 and 22-26.
Trial: NCT03170336
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amiloride first for 8 weeks, then for a washout for 4 weeks, and cross over to receive hydrochlorothiazide for another 8 weeks.
Trial: NCT01943630
Drug: 15% AS101 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Topical 15% AS101 once a day (overnight)